ArticleAnnals of surgical oncology2025
Sleeve Lobectomy, Pulmonary Artery Plasty, and Superior Vena Cava Reconstruction for Locally Advanced Non-small Cell Lung Cancer: A Single-Center Retrospective Study.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundReconstruction of the superior vena cava (SVC) and sleeve resection of the bronchus and pulmonary artery (PA) simultaneously for right upper lobe central-type non-small cell lung cancer (NSCLC) present technical challenges for surgeons. Here, we described our experience with this surgical procedure and the clinical outcomes. PATIENTS AND
methodsWe retrospectively collected clinical data of 15 patients from 31 January 2014 to 30 December 2023 who underwent SVC resection combined with sleeve resection of the bronchus and/or PA. The surgical approaches were described from two typical patients and the overall survival (OS) of those patients was reported.
resultsAmong the 15 patients, 9 (60%) patients received neoadjuvant therapy, and all the patients received adjuvant therapy. All resections were completely resectable (R0). Histologically, seven patients (46.7%) had adenocarcinoma and eight (53.3%) patients had squamous cell carcinoma. In addition, 1 (6.7%) patient was classified as having stage pT4N0M0-IIIA, 12 (80%) were pT4N2M0-IIIB, and 2 were pT4N3M0-IIIC. No perioperative deaths occurred. The major complication rate was 40% after surgery. The median follow-up duration was 29 months, with survival times ranging from 3 to 64 months, and the median survival time was 18 months. In addition, the OS rates at 1, 3, and 5 years were 80%, 28.6%, and 28.6%, respectively.
conclusionsCombined resection of the bronchus, PA, and SVC is technically feasible and safe for patients with locally advanced NSCLC. For carefully selected patients, this extended resection surgery may lead to favorable long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.